Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm and semiconductor stocks. However, market leadership was uneven, mirroring the Tech Bubble: high-beta stocks outperformed while high-quality companies lagged, affecting Conestoga’s quality-focused strategies. Management expressed confidence in long-term outcomes, noting that speculative leadership won’t last as monetary policy tightens and market breadth improves. The firm remains committed to high-quality growth businesses, expecting these to regain favor as leadership broadens. The Conestoga Micro-Cap Composite achieved a solid second quarter with a 22.16% net return, although it underperformed the Russell Microcap Growth Index’s 28.98% return. During this period, Micro-Cap Growth surpassed all major equity benchmarks, which reflects improved investor sentiment towards smaller-cap stocks, but the gains were primarily driven by a limited set of high-beta, high-momentum stocks. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Conestoga Capital Advisors highlighted Artivion, Inc. (NYSE:AORT). Artivion, Inc. (NYSE:AORT) is a global manufacturer and distributor of medical devices and implantable human tissues, which detracted from the portfolio performance during the quarter. On August 6, 2026, Artivion, Inc. (NYSE:AORT) closed at $26.55 per share, reflecting a market capitalization of $1.29 billion. Artivion, Inc. (NYSE:AORT) posted a one‑month return of 14.82%, while its shares lost 32.45% over the past 52 weeks.”
Conestoga Capital Advisors stated the following regarding Artivion, Inc. (NYSE:AORT) in its Q2 2026 investor letter:
“Artivion, Inc. (NYSE:AORT) develops medical devices and implantable tissues used in the treatment of aortic disease. The stock weakened after first quarter stent graft sales fell short of expectations, reflecting slower-than-anticipated AMDS product adoption and softer international demand. Management indicated reorder activity remains strong and expects adoption to accelerate as additional hospitals complete the approval process. We continue to believe AORT’s expanding aortic portfolio and product pipeline provide meaningful long-term growth opportunities.”
Artivion, Inc. (NYSE:AORT) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 28 hedge fund portfolios held Artivion, Inc. (NYSE:AORT) at the end of the first quarter, up from 25 in the previous quarter. Artivion, Inc. (NYSE:AORT) delivered total revenue of $116.3 million in Q1 2026, an increase of 12% on a non-GAAP constant currency basis. While we acknowledge the risk and potential of Artivion, Inc. (NYSE:AORT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Artivion, Inc. (NYSE:AORT) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Artivion, Inc. (NYSE:AORT) and shared Alger Weatherbie Specialized Growth Fund’s insight on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
